single infusion of Rituximab

Phase 1Monoclonal antibody

AAssistance Publique - Hôpitaux de Paris

single infusion of Rituximab is one of 9 small molecule programs targeting Venous malformation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous MalformationNot yet recruiting

Venous MalformationPhase 1

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Venous Malformation

#DrugCompanyPhaseTrials

Depo-Provera

Pfizer

Approved

1 2

Eliquis

Bristol-Myers Squibb

Phase 2

1 3

FCN-159

SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

2 5

Calciparine

BBaxter Healthcare Corporation

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Alcohol

Astellas

Preclinical

—8

single infusion of Rituximab

AAssistance Publique - Hôpitaux de Paris

Phase 1

1 9

Detralex

SServier Russia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Nephrotic Syndrome

NCT05786768

Q4 2028

Phase 1Not yet recruiting

Venous Malformation

NCT07075757

Clinical

Trials by Indication[1]

Venous malformation1 trial

In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07075757·20 enrolled

Nephrotic Syndrome1 trial

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT05786768·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for single infusion of Rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — single infusion of Rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for single infusion of Rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: AAssistance Publique - Hôpitaux de Paris

single infusion of Rituximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Venous malformation1 trial

Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News